<DOC>
	<DOCNO>NCT00200369</DOCNO>
	<brief_summary>The hypothesis study level adherence necessary achieve HIV virologic suppression ritonavir boost protease inhibitor regimen ( i.e . lopinavir/ritonavir ) less 95 % rate observe publish literature unboosted regimen .</brief_summary>
	<brief_title>Characterization Adherence Threshold HIV Suppression Kaletra-based Regimen</brief_title>
	<detailed_description>The exist dogma patient receive highly active antiretroviral therapy ( HAART ) treat HIV infection must take least 95 % prescribed dose order maintain full suppression viral replication . This belief largely base single study perform 1997 1999 ( Ann Int Med 2000 ; 133:21-30 ) . The vast majority patient study receive regimen base either indinavir , nelfinavir , ritonavir , saquinavir . All agent relatively short half-lives , therefore must take time two three time per day . Newer medication lopinavir/ritonavir ( Kaletra ) feature much favorable pharmacokinetic profile . On basis improve pharmacokinetics , reason believe regimens build around agent may forgive missed medication dos . This study aim enroll 90 patient MMC I.D . Clinic either receive receive Kaletra . Patients agree participate furnished MEMS cap , bottle cap electronically record time bottle open store data computer download , undergo electronic monitoring Kaletra adherence period siz month . Adherence data reviewed study , study end ( interim time point ) , investigator analyze MEMS cap data patient complete study order determine threshold value adherence necessary achieve satisfactory rate ( i.e . 70-80 % ) complete virologic suppression . An additional aim study collect specimens patient receive Kaletra base regimen experience virologic failure archive possible study genotypic phenotypic resistance future .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>HIV infection Receiving twice daily Kaletra FDA approve dosage Age &gt; 18 year CD4 viral load available within seven day enrollment Patient willingness accept MEMS cap monitoring HIV genotype within 60 day enrollment patient viral load &gt; 1000 Patient willingness grant inform consent complete five study visit Provider patient deem unlikely Kaletra therapy continue ensue 24 week Prescription medication contraindicate Kaletra recipient</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>HIV</keyword>
	<keyword>Adherence</keyword>
	<keyword>Antiretroviral therapy</keyword>
	<keyword>Protease inhibitor</keyword>
	<keyword>Lopinavir</keyword>
</DOC>